Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...
Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback